Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.50 |
| ▸ | SDHB | P21912 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28928896 | 0.86 | ASIC3 (0.51) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL4895475 | 0.84 | GABRG2 (0.66) | CA12CA1CA2CA9GABRG2 | |
| SCHEMBL28664347 | 0.84 | ASIC3 (0.46) | CA12CA1CA2CA9GABRG2 | |
| SCHEMBL13680584 | 0.83 | GABRG2 (0.53) | CA12CA1CA2CA9GABRG2 | |
| SCHEMBL31224789 | 0.82 | CA12 (0.50) | CA12CA1CA2CA9GABRG2 | |
| SCHEMBL6718372 | 0.82 | CNR1 (0.56) | CA12CA1CA2CA9GABRG2 | |
| SCHEMBL30107993 | 0.82 | CDK8 (0.54) | CA12CA1CA2CA9GABRG2 | |
| SCHEMBL5564786 | 0.81 | ROCK1 (0.63) | CA12CA1CA2CA9GABRG2 | |
| SCHEMBL14890486 | 0.81 | GABRG2 (0.54) | CA12CA1CA2CA9GABRG2 | |
| SCHEMBL28650475 | 0.80 | IL2 (0.48) | CA12CA1CA2CA9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012999-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100227888-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-09 | — | — | US | disclosed |
| US-7754739-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080286204-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-20 | — | — | US | disclosed |
| US-20040006141-A1 | Amidocarboxylic acid compounds | SANKYO COMPANY, LTD (JP) | 2004-01-08 | — | — | US | disclosed |
| US-6528525-B1 | Amidocarboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | disclosed |
| EP-1026149-A1 | AMIDOCARBOXYLIC ACID DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227888-A1 | MODULATORS OF CFTR | CFTR, ABCB1, ABCC4 | CA12 4539/4885CA1 4884/4885CA2 2222/4885 |
| US-20040006141-A1 | Amidocarboxylic acid compounds | NR1H2, AGK, APOL1 | CA12 3105/4885CA1 3246/4885CA2 2273/4885 |
| US-20080286204-A1 | MODULATORS OF CFTR | CFTR, ABCB1, ABCC4 | CA12 4614/4885CA1 4885/4885CA2 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.